top of page
Executive Spotlights

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Technology

Cambridge, MA, March 1, 2023 (PRNewswire) -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion of a $135 million Series B financing led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors.

Read full article here.

Recent Posts

See All
Life Science Headlines
bottom of page